WO2006125531A3 - Thienopyridine - Google Patents

Thienopyridine Download PDF

Info

Publication number
WO2006125531A3
WO2006125531A3 PCT/EP2006/004426 EP2006004426W WO2006125531A3 WO 2006125531 A3 WO2006125531 A3 WO 2006125531A3 EP 2006004426 W EP2006004426 W EP 2006004426W WO 2006125531 A3 WO2006125531 A3 WO 2006125531A3
Authority
WO
WIPO (PCT)
Prior art keywords
hsp90
thienopyridines
medicament
inhibitors
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/004426
Other languages
English (en)
French (fr)
Other versions
WO2006125531A2 (de
Inventor
Hans-Michael Eggenweiler
Michael Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to AU2006251420A priority Critical patent/AU2006251420A1/en
Priority to JP2008512724A priority patent/JP2008542213A/ja
Priority to MX2007014720A priority patent/MX2007014720A/es
Priority to CA002609385A priority patent/CA2609385A1/en
Priority to BRPI0610204-2A priority patent/BRPI0610204A2/pt
Priority to EP06724792A priority patent/EP1888593A2/de
Priority to US11/915,486 priority patent/US7989625B2/en
Publication of WO2006125531A2 publication Critical patent/WO2006125531A2/de
Publication of WO2006125531A3 publication Critical patent/WO2006125531A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Neue Thienopyridinderivate der Formel (I) worin R1, R2, R3, R4 und Y die in Anspruch 1 angegebenen Bedeutungen haben, sind HSP90-lnhibitoren und können zur Herstellung eines Arzneimittels zur Behandlung von Krankheiten, bei denen die Hemmung, Regulierung und/oder Modulation von HSP90 eine Rolle spielt, verwendet werden.
PCT/EP2006/004426 2005-05-27 2006-05-11 Thienopyridine Ceased WO2006125531A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2006251420A AU2006251420A1 (en) 2005-05-27 2006-05-11 Thienopyridines
JP2008512724A JP2008542213A (ja) 2005-05-27 2006-05-11 チエノピリジン
MX2007014720A MX2007014720A (es) 2005-05-27 2006-05-11 Tienopiridinas.
CA002609385A CA2609385A1 (en) 2005-05-27 2006-05-11 Thienopyridines
BRPI0610204-2A BRPI0610204A2 (pt) 2005-05-27 2006-05-11 tienopiridinas
EP06724792A EP1888593A2 (de) 2005-05-27 2006-05-11 Thienopyridine
US11/915,486 US7989625B2 (en) 2005-05-27 2006-05-11 Thienopyridines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005024245.6 2005-05-27
DE102005024245A DE102005024245A1 (de) 2005-05-27 2005-05-27 Thienopyridine

Publications (2)

Publication Number Publication Date
WO2006125531A2 WO2006125531A2 (de) 2006-11-30
WO2006125531A3 true WO2006125531A3 (de) 2007-04-12

Family

ID=36660679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/004426 Ceased WO2006125531A2 (de) 2005-05-27 2006-05-11 Thienopyridine

Country Status (14)

Country Link
US (1) US7989625B2 (de)
EP (1) EP1888593A2 (de)
JP (1) JP2008542213A (de)
KR (1) KR20080021054A (de)
CN (1) CN101163707A (de)
AR (1) AR057332A1 (de)
AU (1) AU2006251420A1 (de)
BR (1) BRPI0610204A2 (de)
CA (1) CA2609385A1 (de)
DE (1) DE102005024245A1 (de)
MX (1) MX2007014720A (de)
RU (1) RU2415859C2 (de)
WO (1) WO2006125531A2 (de)
ZA (1) ZA200711142B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007049451A1 (de) 2007-10-16 2009-04-23 Merck Patent Gmbh 5-Cyano-thienopyridine
US20090118276A1 (en) * 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
GB0908394D0 (en) * 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
KR20130097064A (ko) 2010-09-13 2013-09-02 애버리 데니슨 코포레이션 가열 밀봉 패키징용의 재밀봉가능한 라미네이트
TWI458732B (zh) * 2012-06-27 2014-11-01 國立交通大學 具硼酸基團連接子及含有其之生物感測元件
US9724351B2 (en) 2012-08-23 2017-08-08 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
JP2025516034A (ja) * 2022-05-03 2025-05-26 ユニベルシテ ドゥ ジュネーブ アデノシン２ａ受容体モジュレーターおよびその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034950A1 (en) * 2003-10-10 2005-04-21 Vernalis (Cambridge) Limited Pyridothiophene compounds
WO2005058315A1 (en) * 2003-12-12 2005-06-30 Ribapharm, Inc. Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021552A1 (en) * 2003-08-29 2005-03-10 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
DE102005009440A1 (de) * 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034950A1 (en) * 2003-10-10 2005-04-21 Vernalis (Cambridge) Limited Pyridothiophene compounds
WO2005058315A1 (en) * 2003-12-12 2005-06-30 Ribapharm, Inc. Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
ABBAS A A ET AL: "Versatile starting materials for novel 1,.omega.-bis(pyridin-4- ylphenoxy)alkanes, and their corresponding bis(thieno[2,3-b]pyridin-4- ylphenoxy) derivatives", CAPLUS, 1998, XP002377766 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DYACHENKO, V. D. ET AL: "New route to 6-amino-4-aryl-3,5-dicyanopyridine-2(1H)-thiones", XP002377767, retrieved from STN Database accession no. 1998:310476 *
REGISTRY/STN, 2000, XP002377781 *
REGISTRY/STN, 2000, XP002377782 *
REGISTRY/STN, 2000, XP002377783 *
REGISTRY/STN, 2000, XP002377784 *
REGISTRY/STN, 2001, XP002377775 *
REGISTRY/STN, 2001, XP002377776 *
REGISTRY/STN, 2001, XP002377777 *
REGISTRY/STN, 2001, XP002377780 *
REGISTRY/STN, 2002, XP002377770 *
REGISTRY/STN, 2002, XP002377771 *
REGISTRY/STN, 2002, XP002377772 *
REGISTRY/STN, 2002, XP002377773 *
REGISTRY/STN, 2002, XP002377774 *
REGISTRY/STN, 2004, XP002377768 *
RUSSIAN JOURNAL OF ORGANIC CHEMISTRY (TRANSLATION OF ZHURNAL ORGANICHESKOI KHIMII) , 33(7), 1014-1017 CODEN: RJOCEQ; ISSN: 1070-4280, 1997, XP008066978 *

Also Published As

Publication number Publication date
ZA200711142B (en) 2008-11-26
JP2008542213A (ja) 2008-11-27
MX2007014720A (es) 2008-02-15
AR057332A1 (es) 2007-11-28
EP1888593A2 (de) 2008-02-20
CN101163707A (zh) 2008-04-16
RU2415859C2 (ru) 2011-04-10
DE102005024245A1 (de) 2006-11-30
WO2006125531A2 (de) 2006-11-30
BRPI0610204A2 (pt) 2010-06-01
CA2609385A1 (en) 2006-11-30
AU2006251420A1 (en) 2006-11-30
KR20080021054A (ko) 2008-03-06
US20100048558A1 (en) 2010-02-25
US7989625B2 (en) 2011-08-02
RU2007147593A (ru) 2009-07-10

Similar Documents

Publication Publication Date Title
WO2007134678A3 (de) Triazolderivate ii
WO2002048124A3 (en) Piperazine derivatives
WO2009010139A3 (de) Chinazolinamidderivate
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
EP1889842A4 (de) Heterozyklische verbindung
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
WO2004084453A3 (en) METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
WO2006087077A3 (de) Hsp90 hemmende triazolderivate
WO2008024497A3 (en) INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
WO2006023515A3 (en) Novel thiazole inhibitors of fructose 1,6-bisphosphatase
WO2001023386A3 (de) Benzodiazepin-derivate, deren herstellung und anwendung
WO2003093269A3 (de) Substituierte pyrazolo-pyrimidin-4-one
MX2009013129A (es) Derivados de indazolamida.
WO2004056827A3 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2004101528A3 (en) Isoquinoline derivatives and their use as gfat inhibitors
WO2006122186A3 (en) 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2010066629A3 (en) Novel azaindoles
TW200626598A (en) Pyrrazolo-pyrimidine derivatives
MX2007002324A (es) Derivados de pirrolo[2-3-c]piridina y procesos para la preparacion de los mismos.
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2006047288A3 (en) Asymmetric synthesis of dihydrobenzofuran derivatives
WO2004099197A3 (de) Substituierte oxyarene und deren verwendung zur bekämpfung von schädlingen
WO2009076602A8 (en) 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors
CA2501321A1 (en) Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006724792

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12007501975

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 200680013825.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/014720

Country of ref document: MX

Ref document number: 2609385

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11915486

Country of ref document: US

Ref document number: 2008512724

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 4835/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006251420

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077030243

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007147593

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2006251420

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006251420

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006724792

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0610204

Country of ref document: BR

Kind code of ref document: A2